Stevens Capital Management LP Invests $888,000 in Kenvue Inc. $KVUE

Stevens Capital Management LP acquired a new stake in Kenvue Inc. (NYSE:KVUE) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 42,438 shares of the company’s stock, valued at approximately $888,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Truvestments Capital LLC purchased a new position in Kenvue in the 1st quarter valued at about $37,000. Trust Co. of Vermont grew its holdings in shares of Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after buying an additional 1,150 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd raised its position in shares of Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after buying an additional 1,287 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich lifted its stake in shares of Kenvue by 120.6% during the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company’s stock valued at $41,000 after buying an additional 929 shares during the period. Finally, Ransom Advisory Ltd purchased a new position in shares of Kenvue during the first quarter valued at approximately $56,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $16.63 on Friday. The company has a market cap of $31.86 billion, a price-to-earnings ratio of 22.17, a price-to-earnings-growth ratio of 2.24 and a beta of 0.71. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. The stock’s 50-day moving average is $16.17 and its 200-day moving average is $19.82.

Kenvue (NYSE:KVUE) last issued its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. During the same quarter in the previous year, the business earned $0.28 EPS. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th will be given a $0.2075 dividend. The ex-dividend date of this dividend is Wednesday, November 12th. This represents a $0.83 annualized dividend and a dividend yield of 5.0%. Kenvue’s dividend payout ratio is presently 110.67%.

Analyst Upgrades and Downgrades

Several research firms have commented on KVUE. UBS Group lowered their target price on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, October 8th. The Goldman Sachs Group lowered their price objective on Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a research report on Thursday, October 2nd. Royal Bank Of Canada dropped their target price on Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research note on Friday, August 8th. Johnson Rice reissued a “neutral” rating on shares of Kenvue in a research note on Tuesday, October 28th. Finally, Redburn Partners set a $22.00 price objective on shares of Kenvue in a research note on Friday, September 26th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average price target of $20.23.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.